Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.60 |
| ▸ | RB1 | P06400 | 5/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | DHODH | Q02127 | 2/20 | 0.48 |
| ▸ | BRD3 | Q15059 | 7/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CDC42 | P60953 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4025145 | 0.89 | CYP2D6 (0.58) | CYP2D6RB1KCNH2DHODHBRD3 | |
| SCHEMBL5447185 | 0.88 | RB1 (0.57) | CYP2D6RB1KCNH2BRD3MAPT | |
| SCHEMBL4152538 | 0.85 | CYP2D6 (0.67) | CYP2D6RB1KCNH2DHODHBRD3 | |
| SCHEMBL4142995 | 0.81 | CYP2D6 (0.73) | CYP2D6RB1KCNH2DHODHBRD3 | |
| SCHEMBL4164646 | 0.81 | CYP2D6 (0.63) | CYP2D6RB1KCNH2DHODHBRD3 | |
| SCHEMBL4025627 | 0.80 | RB1 (0.59) | CYP2D6RB1KCNH2DHODHBRD3 | |
| SCHEMBL4024942 | 0.78 | CYP2D6 (0.60) | CYP2D6RB1KCNH2DHODHBRD3 | |
| SCHEMBL4154709 | 0.77 | CYP2D6 (0.67) | CYP2D6RB1KCNH2DHODHBRD3 | |
| SCHEMBL4026175 | 0.77 | CYP2D6 (0.58) | CYP2D6KCNH2DHODHBRD3MAPT | |
| SCHEMBL5458951 | 0.76 | RB1 (0.59) | CYP2D6RB1KCNH2DHODHBRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1646610-B1 | TETRAHYDROCARBAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM CORP (US) | 2009-07-22 | — | — | EP | claimed |
| US-7419997-B2 | Tetrahydrocarbazole derivatives and their pharmaceutical use | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-02 | — | — | US | claimed |
| JP-2007500750-A | — | — | 2007-01-18 | — | — | JP | claimed |
| US-20060148857-A1 | Tetrahydrocarbazole derivatives and their pharmaceutical use | SMITHKLINE BEECHAM CORPORATION | 2006-07-06 | — | — | US | claimed |
| EP-1646610-A1 | TETRAHYDROCARBAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SmithKline Beecham Corporation (US) | 2006-04-19 | — | — | EP | claimed |
| WO-2005005386-A1 | TETRAHYDROCARBAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM CORPORATION (US) | 2005-01-20 | — | — | WO | claimed |
| EP-1646610-B1 | TETRAHYDROCARBAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM CORP (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20090170906-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-02 | — | — | US | disclosed |
| US-20090170906-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-02 | — | — | US | disclosed |
| US-20090170906-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-02 | — | — | US | disclosed |
| US-7419997-B2 | Tetrahydrocarbazole derivatives and their pharmaceutical use | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
| US-7419997-B2 | Tetrahydrocarbazole derivatives and their pharmaceutical use | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
| US-7419997-B2 | Tetrahydrocarbazole derivatives and their pharmaceutical use | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
| EP-1819671-A2 | HCV INHIBITORS WITH CARBAZOLE STRUCTURE | SmithKline Beecham Corporation (US) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006118607-A2 | HCV INHIBITORS WITH CARBAZOLE STRUCTURE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-09 | — | — | WO | disclosed |
| US-20060148857-A1 | Tetrahydrocarbazole derivatives and their pharmaceutical use | SMITHKLINE BEECHAM CORPORATION | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170906-A1 | HCV INHIBITORS | HAVCR2, MAVS, EIF2AK2 | CYP2D6 994/4885RB1 4460/4885KCNH2 4356/4885 |
| US-20060148857-A1 | Tetrahydrocarbazole derivatives and their pharmaceutical use | HMBS, UGT2B17, TPMT | CYP2D6 660/4885RB1 1088/4885KCNH2 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.